ReviewFrontiers in pharmacology2025
Ethnopharmacological insights into uterine fibroids: a review of etiology, and therapeutic potential of natural products.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-Mechanistic Effects of Xylopia aethiopica Fruits on Uterine Fibroids: Insights From In Vivo and In Silico Evidence.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine fibroids (leiomyomas) are the most common benign gynecologic tumors, affecting up to 80% of women by age 50, with higher prevalence and symptom severity reported in women of African descent. These monoclonal tumors originate from smooth muscle cells of the myometrium and are classified based on anatomical location (intramural, submucosal, subserosal, or transmural). Clinical manifestations include abnormal uterine bleeding, pelvic pain or pressure, and infertility. The pathogenesis of fibroids is multifactorial, involving hormonal dysregulation (particularly estrogen and progesterone), MED12 gene mutations, extracellular matrix accumulation, and modifiable risk factors such as vitamin D deficiency and obesity. This review synthesizes current knowledge on fibroid etiology, and treatment strategies, with specific focus on the ethnopharmacological relevance of botanical drugs and natural products. Conventional therapies, including surgery and hormone-based medications, are effective but often associated with high cost, side effects, or loss of fertility. In contrast, natural therapies such as vitamins (D, E), epigallocatechin gallate (EGCG), and plant-based formulations offer promising but underexplored alternatives. Special emphasis is placed on Gunnera perpensa L. [Gunneraceae; Gunnerae perpensae radix] and Albizia tanganyicensis Baker [Fabaceae; Albiziae cortex], two species used in South African traditional medicine for gynecological disorders. Ethnobotanical use, phytochemical profiles, and pharmacological activities including anti-inflammatory, antioxidant, anti-proliferative, and uterotonic properties are critically reviewed. Botanical names have been validated, and data were assessed using the Four Pillars of Best Practice in Ethnopharmacology, the ConPhyMP framework, and the GA checklist for reproducibility and quality assurance. By bridging traditional knowledge with current scientific evidence, this review supports the potential role of culturally rooted botanical drugs in integrative fibroid management and highlights directions for future pharmacological and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.